Inhibikase Therapeutics, Inc.IKT

Key ratios

FCF / Sales

-6947.0%2023

ROA

-32.8%TTM

2025 -20.5%2024 -31.6%2023 -63.7%

ROE

-52.0%TTM

2025 -36.1%2024 -52.0%2023 -118.9%

Revenue growth

-100.0%TTM

2023 111.0%

Recent news

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity 2026-08-11 · GlobeNewswire

Track IKT in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer